Chronic Kidney Disease (CKD) Drugs Market
Number of pages: 100 | Report Format: PDF | Published date: February 23, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 13.2 billion |
|
Revenue Forecast in 2030 |
US$ 19.8 billion |
|
CAGR |
5.2% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Drug Class, Route of Administration, End-user, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global chronic kidney disease (CKD) drugs market was valued at US$ 13.2 billion in 2021 and is expected to register a revenue CAGR of 5.2% to reach US$ 19.8 billion by 2030.
Chronic Kidney Disease (CKD) Drugs Market Fundamentals
A progressive loss of kidney function is a marker of chronic kidney disease (CKD), also known as chronic kidney failure. Wastes and extra fluid are taken from the blood by the kidneys and excreted through the urine. The body may accumulate hazardous fluid, electrolytes, and wastes due to progressive CKD. The early chronic renal disease patient may not have many indications or symptoms. The goal of CKD drugs is to slow the development of kidney damage, generally by addressing the underlying cause. CKD drugs often comprise steps to lessen consequences, control symptoms, and delay the disease’s course.
High blood pressure can get worse in kidney disease patients. The physician might suggest drugs to reduce blood pressure levels. ACE inhibitors or angiotensin II receptor blockers are often used to maintain kidney function. Fluid retention is common in those who have chronic renal disease. This may result in high blood pressure and limb edema. Diuretic medications can aid in maintaining the body’s fluid balance. Moreover, elevated levels of bad cholesterol are commonly found in persons with chronic kidney illness, which can raise their risk of developing heart disease.
[67567567]
Chronic Kidney Disease (CKD) Drugs Market Dynamics
The increasing prevalence of CKDs drives the global chronic kidney disease (CKD) drugs market. The need for novel drugs to enhance patients’ quality of life is rising as the prevalence of chronic renal disease increases. For instance, about 15% of the population in the United States, or around 37 million people, suffer from CKD. Therefore, major companies are concentrating on the development of new drugs and regulatory agency approvals. These initiatives are fueling the global chronic kidney disease (CKD) drugs market revenue growth. For instance, in September 2020, the biopharmaceutical company Ardelyx, Inc. reported that the U.S. Food and Drug Administration (FDA) had approved its new drug application for tenapanor to manage serum phosphorus in adult patients with CKD.
Smoking, unhealthy diet, and physical inactivity may result in the development of CKDs, along with heart disease, stroke, diabetes, obesity, and metabolic syndrome. Thus, increasing smoking and consumption of alcohol influence the revenue growth of the global market.
The rising global elderly population, which is more sensitive to cardiovascular illnesses due to the prevalence of diabetes co-morbidities, is a significant factor impacting the global chronic kidney disease (CKD) drugs market revenue growth. The proportion of persons over 65 is rising significantly worldwide, and renal illnesses are becoming increasingly common among older adults. On the other hand, when it comes to the renal filtration process, drugs, and alcohol are not an exception to coming directly in contact with the kidneys. In fact, the kidneys are where the majority of abused substances are removed. Long-term usage of medications that are commonly used to treat heart attacks, congestive heart failure, excessive blood pressure, and other conditions, as well as to avoid serious cardiac issues, are reported to have a severe effect on kidneys, developing CKDs. Therefore, increased usage of multiple drugs to treat different other diseases can affect kidney functions significantly, which drives the revenue growth of the global chronic kidney disease (CKD) drugs market.
However, a lack of knowledge about renal problems and high treatment costs limit the revenue growth of the global chronic kidney disease (CKD) drugs market.
Chronic Kidney Disease (CKD) Drugs Market Ecosystem
The global chronic kidney disease (CKD) drugs market is analyzed from four perspectives: drug class, route of administration, distribution channel, and region.
Chronic Kidney Disease (CKD) Drugs Market by Drug Class
[8567575]
Based on the drug class, the global chronic kidney disease (CKD) drugs market is segmented into ACE inhibitors, angiotensin-II receptor blockers, beta-blockers, calcium channel blockers, diuretics, erythropoiesis-stimulating agents (ESAs), and others.
The calcium channel blockers segment accounted for the largest revenue share for the global chronic kidney disease (CKD) drugs market in 2021. The ability of calcium channel blockers (CCBs) to lower blood pressure has led to their widespread usage in clinical practice. One of the most important objectives of antihypertensive therapy is to prevent kidney damage. This is especially true considering the significant frequency of chronic renal disease in the general population. Several studies have connected CKD to the metabolic syndrome’s clustering of extra cardiovascular risk factors and inadequate blood pressure control. Among the potential antihypertensive drug classes presently offered for the clinical management of CKD, both in monotherapy and combination therapy, drugs inhibiting the CCBs are effective and safe in lowering blood pressure levels and achieving the recommended blood pressure targets with a good tolerability profile. CCBs have become one of the most widely used antihypertensive medications over the past 20 years due to their effectiveness in lowering blood pressure levels, good tolerability, and strong evidence of reducing hypertension’s cardiovascular and renal effects.
Chronic Kidney Disease (CKD) Drugs Market by Route of Administration
Based on the route of administration, the global chronic kidney disease (CKD) drugs market is segmented as oral, subcutaneous, and intravenous.
The oral segment accounted for the largest revenue share for the global chronic kidney disease (CKD) drugs market in 2021. The most popular method of medication administration is oral. This is the most method for treatment due to its benefits, including non-invasiveness, patient compliance, and ease of medication delivery. Thus, the rise in the advantages of oral drug administration is fueling revenue growth in the segment.
Chronic Kidney Disease (CKD) Drugs Market by Distribution Channel
Based on the distribution channel, the global chronic kidney disease (CKD) drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
Hospital pharmacies play a critical role in maximizing patient care by collaborating with doctors, nurses, and other healthcare workers to supply the right medications and supplies in accordance with established treatment procedures. When it comes to patient care, hospital pharmacists are doing better, providing more medication-related interventions for patient transitions round-the-clock. Confirmation of medication instructions and medication counseling are also part of these advantages. Ensuring patients understand how to take their medications appropriately is critical for their health outcomes and can lower the possibility of hospital readmissions. Hospital pharmacies can be crucial in helping patients receive drug counseling, which eventually helps the healthcare system save money.
Chronic Kidney Disease (CKD) Drugs Market by Region
Based on the region, the global chronic kidney disease (CKD) drugs market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America accounted for the largest revenue share of the global chronic kidney disease (CKD) drugs market in 2021. The main factors driving the market’s growth in the United States are the expanded government initiatives and the upgraded healthcare infrastructure, which provide favorable reimbursement policies. Rising rates of chronic renal disease, a developed healthcare system, high health spending, and technologically sophisticated diagnostic procedures are the main drivers of market revenue growth in North America. The primary driver fueling the market’s expansion is the rising prevalence of chronic kidney disorders in the population. For instance, according to the Centers for Disease Control and Prevention (CDC), kidney diseases are a primary cause of death in the U.S. Moreover, there are about 37 million cases of CKD in the U.S., and most of them go untreated. Also, around 40% of individuals with significant renal impairment (not receiving dialysis) are unaware that they have CKD.
Chronic Kidney Disease (CKD) Drugs Market Competitive Landscape
The key players operating in the chronic kidney disease (CKD) drugs market are:
Chronic Kidney Disease (CKD) Drugs Market Strategic Developments
CKD drugs are used to treat continuing kidney failure by delaying the development of kidney damage. These drugs generally address the underlying causes, such as high blood pressure and diabetes.
The increased prevalence of CKDs, several lifestyle disorders, such as obesity and diabetes, and the rise in the geriatric population are the key trends driving the revenue growth of the global chronic kidney disease (CKD) drugs market.
AstraZeneca plc., Pfizer Inc., Amgen Inc., FibroGen, Inc., and GlaxoSmithKline plc. are among the top market players.
Th high cost of drugs and lack of awareness are two major factors responsible for hindering the revenue growth of the global chronic kidney disease (CKD) drugs market to its full potential.
The global chronic kidney disease (CKD) drugs market is expected to grow at a revenue CAGR of 5.2% during the forecast period from 2020 to 2030.
*Insights on financial performance are subject to the availability of information in the public domain